Clinical trials: SAR-CoV-2
SAR-CoV-2, Cellular Immune Response
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Twelve months after the first SARS-CoV-2 cases in Wuhan, the FDA approved the first COVID-19 vaccine (Pfizer-BioNTech). Early studies on healthcare workers showed that antibody levels, especially against the Spike protein…
- Conditions
- SAR-CoV-2, Cellular Immune Response, Antibody Response
- Trial name
- BioVAC-immunit (NCT07049497)
- Testing
- Evaluation of the T cell response in terms of IFN-γ measured by ELISpot
- Where
- Italy
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Stroke, Acute
Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic
TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center (TELECAST-CSC) during the COVID-19 pandemic is a pre-post study evaluating guideline-based acute ischemic stroke care following the implementation of…
- Trial name
- TELECAST-CSC (NCT04761874)
- Testing
- Telestroke
- Where
- United States
- Volunteers
- 296 people
- Sponsor
- University of Minnesota
Virus Diseases
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases.
- Trial name
- COVIMAR (NCT04710199)
- Testing
- Maraviroc experimental group, Standard treatment
- Where
- 2 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Asymptomatic Infections, SARS-CoV2 Infection
Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection
This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai…
- Trial name
- IDRA-COVID19 (NCT04435587)
- Testing
- Ivermectin Pill, Combined ART/hydroxychloroquine
- Where
- 4 sites in Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
Influenza A, Influenza B
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges…
- Conditions
- Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs)
- Trial name
- TreatResp (NCT07314905)
- Testing
- Baloxavir
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Unity Health Toronto
COVID-19, SAR-CoV-2
Long-term Effects of COVID-19
The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients…
- Trial name
- NCT05220514
- Testing
- (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Mayo Clinic
COVID-19
Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19
Background: The COVID-19 pandemic has challenged the health systems worldwide. Many tools have been developed in response to the pandemic, but there is no current way to quickly screen multiple people for the disease.
- Trial name
- NCT05044780
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)